The Use of Paclitaxel-Coated Devices in the Treatment of Peripheral Arterial Disease Is Not Associated with Increased Mortality or Amputations

Strategies for the most effective treatment for peripheral arterial disease (PAD) remain controversial among clinicians. Several trials have shown improved primary patency of femoropopliteal interventions with the utilization of paclitaxel-coated balloons or stents (DCBS) compared to conventional balloons or stents. However, a 2018 meta-analysis suggested an increased mortality risk for patients receiving DCBS, resulting in an international pause in the use of DCBS. A 2021 meta-analysis by the same group suggested an increased risk of major amputation following DCBS use in peripheral arterial revascularization procedures.

Source: Annals of Vascular Surgery - May 16, 2022 Category: Surgery Authors: Evan C. Bair, Beau C. McCarver, Neal T. Cooper, Benjamin A. Greif, Matthew Major, Shengxuan Wang, Anthony J. Lewis, Evan J. Ryer, James R. Elmore, Gregory G. Salzler Tags: Clinical Research Source Type: research